BORTEZOMIB FRESENIUS KABI 3.5 MG Israel - English - Ministry of Health

bortezomib fresenius kabi 3.5 mg

neopharm (israel) 1996 ltd - bortezomib - powder for solution for injection - bortezomib 3.5 mg/vial - bortezomib - multiple myelomabortezomib fresenius kabi is indicated for the treatment of adult patients with multiple myeloma.mantle cell lymphomabortezomib fresenius kabi for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib fresenius kabi in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Etoposide 20 mg/ml concentrate for solution for infusion Ireland - English - HPRA (Health Products Regulatory Authority)

etoposide 20 mg/ml concentrate for solution for infusion

fresenius kabi oncology plc - etoposide - concentrate for solution for infusion - 20 milligram(s)/millilitre - podophyllotoxin derivatives; etoposide

IRINOTECAN HYDROCHLORIDE 20 MG/ML CONCENTRATE FOR Ireland - English - HPRA (Health Products Regulatory Authority)

irinotecan hydrochloride 20 mg/ml concentrate for

fresenius kabi oncology plc - irinotecan hydrochloride trihydrate - solution for infusion - 20 micromol - irinotecan

BENDAMUSTINE HCL Ireland - English - HPRA (Health Products Regulatory Authority)

bendamustine hcl

fresenius kabi oncology plc - bendamustine hydrochloride - pdr/conc/soln for infus - 25 milligram - bendamustine